More n is required, yes, but small n results like this are a noteworthy step in the right direction.
There is often good reason why n is small. Statistically significant results like this one pave the way to future experiments with larger n.
It seems that running these 'small batch' studies/trials can be tremendously helpful to inform and refine the approach before executing on a larger scale. Of course if it takes 3 years to reach an endpoint it probably doesn't make sense to serialize them, but to my layman perspective there appears to be clear value (and in this case encouraging results).
Small n studies are often the most exciting. If you get a p<0.01 effect in 10 people vs. 10000 people... the lower bound of the effect size is similar, and so for the same prior each study should change our belief by a similar amount... but the upper bound of effect size is much larger in the large study.
The only thing that messes this logic of mine up a bit is publication bias. There's a much larger chance that small studies sit on the shelf unpublished if there's no clear effect.
Sure, though one aspect of the depression scales is (self-reported) ability to go about daily activities, get normal sleep, etc-- not just "feeling down". That is, it's self-reported information on functionality, too.
- Building upon mounting evidence of TMS efficacy in patients with severe, intractable depression.
- 79%-- 11 of the 14-- no longer meeting diagnostic criteria for depression after treatment, and another was improved.
- It's an RCT showing both massive efficacy and statistical significance. (2 of 14 in placebo group entered remission).
I know we like to chant "more n"-- but this is very likely to be both real and a clinically useful finding.